Focus: Passkey Therapeutics is a Cambridge-based biotechnology company focused on multifunctional therapeutic technology across immunology, oncology, respiratory, neurology, and hematology indications. The company operates a portfolio of generic and branded products with heavy concentration in a single corticosteroid asset.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Passkey Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Passkey Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Accounts for 84% of company revenue; post-loss-of-exclusivity generic with limited pricing power and exposure to generic competition.
Help build intelligence for Passkey Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Branded combination analgesic generating minimal revenue; post-LOE positioning limits market exclusivity.
NDA-approved antiplatelet therapy approaching loss of exclusivity in December 2027; minimal current revenue with imminent patent cliff.
Generic combination analgesic with no disclosed Part D spending; post-LOE lifecycle with no growth profile.
Generic combination analgesic with no disclosed Part D spending; post-LOE lifecycle with no growth profile.
Branded generic combination analgesic with no disclosed Part D revenue; post-LOE status with limited market differentiation.
Generic barbiturate-containing headache therapy with no disclosed Part D revenue; regulatory scrutiny on barbiturate combinations limits growth.
Generic combination analgesic with no disclosed Part D spending; post-LOE lifecycle with no growth profile.
Generic combination analgesic with no disclosed Part D spending; post-LOE lifecycle with no growth profile.
Generic combination analgesic with no disclosed Part D spending; post-LOE lifecycle with no growth profile.
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo